Xenitra Limited’s FY2026 results reveal a deeper loss and halved revenue, but a sharper focus on higher-margin OTC medicines and tokenisation signals a turning point in its turnaround.
- Revenue down 49.4% to $20.1 million
- Loss after tax widens 48.9% to $5.18 million
- Second-half revenue jumps 64% on leaner cost base
- OTC Medicines and OPAL tokenisation platforms launched
- Secured $12 million Kangsheng procurement deal post-year-end
Financials Reflect Transition, Not Triumph
Xenitra Limited (ASX:XEN), formerly Aumake, posted a $5.18 million loss after tax for FY2026, a 48.9% increase from the prior year’s $3.48 million loss. Revenue halved to $20.1 million from $39.8 million, reflecting a deliberate pause in trading during Q2 to recalibrate its business model.
Yet beneath the headline figures lies a narrative of transformation. The company slashed Australian corporate costs by over $1 million annually, trimming board and management expenses from $1.3 million to below $600,000, and eliminated legacy travel and entertainment spend. This leaner structure underpinned a 64% revenue surge in H2, from $7.63 million to $12.47 million, alongside a 42% reduction in losses between halves, signalling improved operating leverage.
Pivot to Higher-Margin Growth Platforms
Xenitra’s strategic reset centres on three pillars: Nutritionals, OTC Medicines, and the OPAL blockchain-enabled sales ecosystem. Nutritionals remains the revenue backbone but with lower margins, while OTC Medicines and OPAL represent higher-margin, capital-efficient growth engines.
The acquisition of Hong Kong Fukang Trading Co. in April 2026 was pivotal, converting regulatory groundwork into a functioning OTC platform. Post-year-end, Fukang secured a three-year procurement deal worth a minimum of A$12 million with Kangsheng Hong Kong International Trading Limited, validating the commercial viability of Xenitra’s healthcare expansion. Additionally, a three-year A$5 million framework agreement with Joy Charm Limited broadens exposure into specialised medical nutrition products.
OPAL, launched in April 2026, has rapidly onboarded over 500 distributors and generated more than A$1.5 million in tokenised product sales within its first quarter, reflecting early traction in integrating blockchain technology with traditional distribution channels.
Governance Overhaul and Board Renewal
Governance reforms accompanied the operational turnaround. The Board strengthened its oversight capabilities by appointing experienced directors Carl Hagon and Zoran Grujic, and clarified the separation between executive management and board responsibilities. Former executive directors stepped down to focus on operational execution, notably Tracy Zhang, who leads the China business unit.
This governance refresh aligns with the company’s shift from costly joint ventures to wholly owned subsidiaries, enhancing transparency and accountability for capital deployment.
Capital Raising to Fuel Growth Execution
Xenitra raised A$1.25 million in May 2026 and secured commitments for a further A$1.5 million placement in August 2026. These funds are earmarked for inventory build, supplier capacity, fulfilment, e-commerce activation, and onboarding across OTC Medicines, FSMP, and OPAL channels. Unlike prior capital injections aimed at sustaining overheads, this funding supports execution in a leaner, cash-flow-positive business model, as evidenced by Q4’s positive operating cash flow of approximately A$800,000.
Outlook Hinges on Sustaining Momentum
While FY2026’s financials reflect the costs of transformation, the company’s narrative is one of cautious optimism. The Board’s priorities for FY2027 focus on converting strategic partnerships into repeatable revenue streams, improving gross margins, maintaining cost discipline, and progressing toward sustainable profitability.
However, the widened loss and halved revenue underscore the challenges ahead. The success of new platforms like OTC Medicines and OPAL will be critical to reversing the company’s financial trajectory. The market will watch closely how Xenitra manages working capital, regulatory compliance, and execution risks inherent in scaling multiple growth initiatives simultaneously.
With a fundamentally different structure and strategy, Xenitra aims to transition from turnaround to growth, but the path remains to be proven in the coming quarters.
Investors should note that no dividends were declared or paid during FY2026, consistent with the company’s focus on reinvestment and recovery.
Notably, the company’s latest capital raising and the Kangsheng procurement agreement mark tangible progress in commercial execution, offering early signs that the strategic reset is gaining traction.
As Xenitra moves into FY2027, the critical question remains: can it translate early momentum into consistent cash generation and profitability?
Bottom Line?
Xenitra’s FY2026 results highlight a company in mid-turnaround, costs are down and new platforms are gaining traction, but profitability remains elusive.
Questions in the middle?
- Will Xenitra’s OTC Medicines platform sustain growth and margin improvement amid competitive and regulatory challenges?
- Can the OPAL tokenisation ecosystem scale sufficiently to materially impact overall profitability?
- How effectively will the company manage working capital and supply chain risks as it expands its product portfolio and geographic reach?